Owlet® Announces Strategic AI Partnership with webAI to Power the Next Generation of Personalized Infant Health and Sleep Insights

Key Terms

private ai infrastructure technical

Private AI infrastructure is the hardware, software and networking a company builds or leases to run artificial intelligence models and data inside its own controlled environment rather than using public cloud services. For investors it matters because it affects cost, speed, data privacy and competitive advantage—like owning a factory versus renting workshop space: owning can lower long‑term costs and protect secrets but requires bigger upfront investment and upkeep.

proprietary data technical

Proprietary data is information a company owns or controls that isn’t publicly available—like customer lists, internal measurements, or results from unique sensors and models. For investors it matters because exclusive data can act like a company’s “secret recipe,” helping it make better decisions, offer unique products, defend market share, and generate revenue; conversely, loss of exclusivity or legal limits on use can reduce that advantage.

enterprise-grade ai technical

Enterprise-grade AI is an artificial intelligence system built for use across a whole business, designed to be reliable, secure, and scalable under heavy workloads. Think of it as an industrial-strength tool rather than a consumer gadget: it handles large volumes of data, meets legal and privacy rules, and integrates with existing systems. Investors care because these qualities reduce operational risk, support growth, and can create durable cost savings or competitive advantage.

longitudinal data medical

Longitudinal data are measurements collected from the same people, companies, products, or locations repeatedly over time, like taking regular snapshots of a plant’s growth rather than a single photo. For investors, this kind of data reveals trends, persistence, and cause-and-effect patterns that a one-time measurement can miss, improving forecasts, risk assessment, and the ability to judge whether changes are temporary or likely to continue.

pulse oximeter medical

A pulse oximeter is a small medical device that clips onto a fingertip or earlobe and uses light to estimate how much oxygen is in the blood and the wearer’s pulse rate. Investors care because it’s a common, often reimbursed piece of diagnostic equipment whose sales and pricing reflect healthcare demand, regulatory approvals, supply chains and consumer adoption—similar to how fuel gauges signal a car’s readiness and maintenance needs.

Strategic investment in private AI infrastructure positions Owlet to compound value from its growing base of proprietary infant wellness data

LEHI, Utah--(BUSINESS WIRE)-- Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced a strategic partnership with webAI, a leading private AI platform, to accelerate the development of secure, personalized, and data-driven intelligence across the Owlet product ecosystem.

The partnership represents a foundational step in Owlet’s long-term AI strategy, focused on leveraging the Company’s proprietary infant health and sleep data to deliver tailored insights for families while building durable, differentiated platform capabilities over time. By investing in enterprise-grade AI infrastructure, Owlet aims to responsibly unlock the value of its unique, vast infant wellness dataset, enabling increasingly personalized experiences for parents and caregivers.

“We view AI as a long-term platform investment that strengthens Owlet’s competitive position and further empowers parents in the care of their children,” said Jonathan Harris, President and CEO of Owlet. “Partnering with webAI will accelerate our ability to build private, enterprise-grade intelligence directly on our data, an approach that prioritizes security, scalability, and durability. As our dataset continues to grow, we believe this foundation will allow us to deliver increasingly differentiated insights for families around the world.”

Building AI as a Core Platform Capability

Owlet selected webAI as a strategic AI partner based on the platform’s deep expertise in private AI systems purpose-built for sensitive-data environments. Trusted by leading consumer health companies, webAI enables companies to train intelligence on proprietary data and operate it on its owned and controlled infrastructure. This approach is designed to ensure data privacy, regulatory alignment, and scalability as Owlet expands its connected hardware and software elements globally.

Key elements of the partnership include:

• Private, enterprise-grade AI architecture designed to operate on Owlet’s proprietary data
• Security-first infrastructure tailored for sensitive information
• Custom intelligence optimized for sleep and health insights
• A scalable AI foundation to support multiple future products and services across the Owlet ecosystem

By training AI on its growing base of longitudinal data, Owlet expects insights to become increasingly accurate, personalized, and differentiated over time, reinforcing a data advantage and creating long-term value for its users.

“webAI is a private AI platform designed for organizations working with sensitive, proprietary data just like Owlet,” said David Stout, CEO at webAI. “Owlet has built a trusted platform in infant health with a unique depth of pediatric data, and we’re proud to partner with the Company to unlock specialized intelligence that improves with every interaction, while keeping family data protected.”

Positioning Owlet for Long-Term Value Creation

Owlet views AI as a core platform capability, not a standalone feature, that will increasingly power consumer experiences, insights, and services. The Company believes this disciplined, security-first approach positions Owlet to responsibly harness AI while maintaining trust with both families and stakeholders.

To learn more about Owlet and its line of pediatric smart baby monitoring devices, including the best-selling FDA-cleared Dream Sock^® and prescription pulse oximeter BabySat^®, please visit www.owletcare.com.

About Owlet, Inc.

Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.

About webAI

webAI is the sovereign enterprise AI platform that brings AI to your data. Built for mission-critical environments, it enables organizations to build and operate private, custom models with complete data sovereignty, real-time performance, and predictable economics. From public sector and defense to healthcare and manufacturing, webAI powers specialized AI that enterprises truly own.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s strategic partnership with webAI and the anticipated impacts thereof; the Company’s expectations regarding the development, timing, and performance of AI-enabled features, insights, products, and services across its ecosystem; and the Company’s ability to leverage its data to enhance personalization and user experience while maintaining privacy, security, and regulatory compliance; the Company’s ability to expand availability of its products and services in additional markets; and the Company’s ability to enhance its technology, product ecosystem, and service offerings over time. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “continues,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to: (i) the commercial success of Owlet’s products, including any new AI-enabled features, insights, products, or services, and the Company’s ability to support, scale and maintain its products island services, including any subscription or software-enabled offerings; (ii) the Company’s ability to develop, integrate, and deploy AI-enabled capabilities on the expected timeline, or at all, and to achieve the anticipated benefits from the partnership; (iii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and comply with ongoing regulatory requirements; (iv) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information, and risks of cybersecurity incidents or changes in applicable standards or interpretations; (v) the performance of, and Owlet’s ability to maintain and expand, its relationship with third-party technology, cloud, manufacturing and distribution partners; (vi) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vii) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (viii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (ix) Owlet’s ability to maintain relationships with channel partners, customers, manufacturers and suppliers; (x) impacts from compliance with applicable laws or regulations; (xi) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xii) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xiii) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260203759621/en/

Owlet Media Contact:

pr@owletcare.com



Owlet Investor Contact:

ir@owletcare.com

webAI Media Contact:

press@webai.com

Source: Owlet, Inc.